Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis
Key facts
- Who runs it
- Xijing Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 60 people enrolled
- Started
- 1 Oct 2023
- Ended
- 16 Jul 2025
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Minocycline
- Record updated
- 14 August 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Diagnosis of definite autoimmune encephalitis(Graus et al 2016.)
- Age ≥ 18 years
- Acute or subacute onset (rapid progression of less than 3 months)
- Reasonable exclusion of alternative causes
- Written informed consent
Who cannot take part
- Uncontrolled serious concomitant illness
- Known allergy to tetracycline antibiotics
- Known chronic kidney disease stages 3b-5
- Moderate liver disease (see Child-Pugh for Classification of Severity of Liver Disease)
- history of cognitive impairment
- Pregnant women
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Autoimmune encephalitis (AE) is an immune-mediated brain disorder characterized by varied clinical manifestations that correlate with specific types of antibodies.Typical symptoms include acute behavioral changes, psychosis, seizures, memory deficits, dyskinesias, speech impairments, and autonomic and respiratory dysregulation.While the majority of patients respond well to immunotherapeutic agents, a significant proportion remains resistant to initial and secondary-line immunotherapies.Minocycline, a semisynthetic tetracycline, is notably used for the central nervous system due to its lipophilic characteristics and its capacity to penetrate the blood-brain barrier. While the primary neuroprotective focus of minocycline in the central nervous system remains unknown, the primary effects of minocycline include the inhibition of microglial activation, mitigation of apoptosis, and reduction in reactive oxygen species generation.Protective effect has been observed in hypoxic injury, ischemic stroke, amyotrophic lateral sclerosis, traumatic spinal cord injury, multiple sclerosis, Parkinson's disease, and Huntington's disease.Can minocycline offer a protective role in AE? Consequently, we proposed a randomized, controlled trial to investigate the efficacy of minocycline in AE.
The 2 groups in the trial
- Experimental: Treatment groupTreatment being tested
Drug: Minocyclin 200 mg oral minocycline for a total of 30 days
Treatment: Minocycline
- Control groupNo study treatment, for comparison
first-line drugs for autoimmune encephalitis
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis: Open-lable, Randomised, Proof of Concept Study
- Publications
- Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis (MEET): A Proof of Concept Study.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2026
- Record updated
- 14 August 2025